Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986259 in stabilized hospitalized patients with acute decompensated heart failure
NL-OMON49097Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure (HF) comparing BMS-986259 with Placebo (2 arms). Primary endpoint: Incidence of clinically relevant hypotension. Started Mar 2021; status: completed.
02
Drugs
FA relaxin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NL-OMON49097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49097.